May disrupt tumor pH regulation—by inhibiting vacuolar-type H+-ATPases in cancer cells—which can alter drug uptake/resistance and potentially sensitize tumors (e.g., gliomas) [160,161]. The gene discussed is ATP6V1A; the disease is central nervous system cancer.